To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Vertex Pharmaceuticals Inc.

(VRTX)

Cowen & Co. analyst David Stone said the Cambridge, Mass., company's HIV protease inhibitor,

VX-478

, is potentially superior to Merck's drug.

In 28-day primate studies, VX-478 was

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE